Transcription factor NF-κB in glomerulonephritis

Nephrology

Volumn 5, Issue 1-2, 2000, Pages 71-82

  Auwardt, Russell B ^a   Mudge, Stuart J ^a   Power, David A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Chemokines; Cytokines; Glomerulonephritis; Inflammation; Nuclear factor kappa B; Steroids; Transcription

Indexed keywords

CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STEROID;

GENE ACTIVATION; GLOMERULONEPHRITIS; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

EID: 0034102935     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2000.00518.x     Document Type: Review

References (86)

1. 1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-16.
2. 2. Baeuerle PA, Baichwal VR. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 1997; 65: 111-37.
3. 3. Akira S, Kishimoto T. NF-IL6 and NF-κB in cytokine gene regulation. Adv. Immunol. 1997; 65: 1-46.
4. 4. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol. Today 1998; 19: 80-8.
5. 5. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998; 16: 225-60.
6. 6. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. ReI/NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev. 1995; 9: 2723-35.
7. 7. Whiteside ST, Epinat JC, Rice NR, Israel A. IκB-ε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 1997; 16: 1413-26.
8. 8. Simeonidis S, Liang S, Chen G, Thanos D. Cloning and functional characterization of mouse IκB-ε. Proc. Natl Acad. Sci. USA 1997; 94: 14372-7.
9. 9. Li Z, Nabel GJ. A new memher of the IκB protein family, IκB-ε, inhibits RelA (p65) -mediated NF-κB transcription. Mol. Cell. Biol. 1997; 17: 6184-90.
10. 10. Chen CG, Malliaros J, Katerelos M, d'Apice AJ, Pearse MJ. Mutation at ser32 of IκB-α blocks NF-κB activation. Transplant. Proc. 1996; 28: 615-6.
11. 11. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκB-α by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84: 853-62.
12. 12. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKB, necessary for IκB phosphorylation and NF-κB activation. Cell 1997; 91: 243-52.
13. 13. Stancovski I, Baltimore D. NF-κB activation: the IκB kinase revealed? Cell 1997; 91: 299-302.
14. 14. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 1998; 395: 297-300.
15. 15. Baldi L, Brown K, Franzoso G, Siebenlist U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκB-α. J. Biol. Chem. 1996; 271: 376-9.
16. 16. Cheng Q, Cant CA, Moll T et al. NF-κB subunit-specific regulation of the IκB-α promoter. J. Biol. Chem. 1994; 269: 13551-7.
17. 17. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of IκB-α activity. Proc. Natl Acad. Sci. USA 1994; 91: 28-32.
18. 18. Ito CY, Kazantsev AG, Baldwin AS Jr. Three NF-κB sites in the IκB-α promoter are required for induction of gene expression by TNF-α. Nucleic Acids Res. 1994; 22: 3787-92.
19. 19. Le Bail O, Schmidt-Ullrich R, Israel A. Promoter analysis of the gene encoding the IκB-α/MAD3 inhibitor of NF-κB: positive regulation by members of the rel/NF-κB family. EMBO J. 1993; 12: 5043-9.
20. 20. Read MA, Whitley MZ, Williams AJ, Collins T. NF-κB and IκBα: An inducible regulatory system in endothelial activation. J. Exp. Med. 1994; 179: 503-12.
21. 21. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-κB controls expression of inhibitor IκB-α: Evidence for an inducible auto-regulatory pathway. Science 1993; 259: 1912-5.
22. 22. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized IκB-α negatively regulates DNA-binding and transcriptional activities of NF-κB. Mol. Cell. Biol. 1995; 15: 2689-96.
23. 23. Beg AA, Baldwin AS Jr. Activation of multiple NF-κB/Rel DNA-binding complexes by tumor necrosis factor. Oncogene 1994; 9: 1487-92.
24. 24. Johnson DR, Douglas I, Jahnke A, Ghosh S, Pober JS. A sustained reduction in IκB-β may contribute to persistent NF-κB activation in human endothelial cells. J. Biol Chem. 1996; 271: 16317-22.
25. 25. Auwardt RB, Mudge SJ, Chen CG, Power DA. Regulation of NF-κB by corticosteroids in rat mesangial cells. J. Am. Soc. Nephrol. 1998; 9: 1620-8.
26. 26. Tran K, Merika M, Thanos D. Distinct functional properties of IκB-α and IκB-β. Mol. Cell. Biol. 1997; 17: 5386-99.
27. 27. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 1995; 80: 573-82.
28. 28. Baeuerle PA, Baltimore D. NF-κB: Ten years after. Cell 1996; 87: 13-20.
29. 29. Schwarz EM, Krimpenfort P, Berns A, Verma IM. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 1997; 11: 187-97.
30. 30. Roy-Chaudhury P, Wu B, King G et al. Adhesion molecule interactions in human glomerulonephritis: Importance of the tubulointerstitium. Kidney Int. 1996; 49: 127-34.
31. 31. Baraldi A, Zambruno G, Furci L et al. β1 and β3 integrin upregulation in rapidly progressive glomerulonephritis. Nephrol. Dial. Transplant. 1995; 10: 1155-61.
32. 32. Parra G, Romero M, Henriquez-La Roche C, Pineda R, Rodriguez-Iturbe B. Expression of adhesion molecules in poststreptococcal glomerulonephritis. Nephrol. Dial. Transplant. 1994; 9: 1412-7.
33. 33. Dal Canton A. Adhesion molecules in renal disease. Kidney Int. 1995; 48: 1687-96.
34. 34. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-α is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am. J. Pathol. 1995; 146: 1444-54.
35. 35. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997; 63: 414-20.
36. 36. Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am. J. Kidney Dis. 1996; 27: 640-6.
37. 37. Yoshioka K, Takemura T, Murakami K et al. In situ expression of cytokines in IgA nephritis. Kidney Int. 1993; 44: 825-33.
38. 38. Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-κB in experimental glomerulonephritis in rats. Biochim. Biophys. Acta 1996; 1316: 132-8.
39. 39. Sakurai H, Shigemori N, Hisada Y, Ishizuka T, Kawashima K, Sugita T. Suppression of NF-κB and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: Molecular mechanisms of anti-nephritic action. Biochim. Biophys. Acta 1997; 1362: 252-62.
40. 40. Seto M, Kim S, Yoshifusa H et al. Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. J. Am. Soc. Nephrol. 1998; 9: 1367-76.
41. 41. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through NF-κB activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 1998; 161: 430-9.
42. 42. Ward C, Chilvers ER, Lawson MF et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J. Biol. Chem. 1999; 274: 4309-18.
43. 43. Sugiyama H, Savill JS, Kitamura M, Zhao L, Stylianou E. Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappaB in primary glomerular mesangial cells. J. Biol. Chem. 1999; 274: 19532-7.
44. 44. Dudley E, Hornung F, Zheng L, Scherer D, Ballard D, Lenardo M. NF-kappaB regulates Fas/APO-1/CD95-and TCR-mediated apoptosis of T lymphocytes. Eur. J. Immunol. 1999; 29: 878-86.
45. 41 Wu M, Lee H, Bellas RE et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996; 15: 4682-90.
46. 46. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of NF-κB-dependent transcription involves direct interference with transactivation. Proc. Natl Acad. Sci. USA 1997; 94: 13504-9.
47. 47. Scheinman RI, Gualberto A, Jewell CM, Cidlouwski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell. Biol. 1995; 15: 943-53.
48. 48. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol. Cell. Biol. 1990; 10: 1498-506.
49. 49. Kato M, Schleimer RP. Antiinflammatory steroids inhibit granulocyte/macrophage colony-stimulating factor production by human lung tissue. Lung 1994; 172: 113-24.
50. 50. Caldenhoven E, Liden J, Wissink S et al. Negative cross-talk between RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 1995; 9: 401-12.
51. 51. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H. Glucocorticoids inhibit E-selectin expression by targeting NF-κB and not ATF/c-Jun. J. Immunol. 1997; 158: 3836-44.
52. 52. Wissink S, van Heerde EC, vand der Burg B, van der Saag PT. A dual mechanism mediates repression of NF-κB activity by glucocorticoids. Mol. Endocrinol. 1998; 12: 355-63.
53. 53. Vacca A, Felli MP, Farina AR et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J. Exp. Med. 1992; 175: 637-46.
54. 54. Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J. Clin. Invest. 1993; 91: 1481-9.
55. 55. Rolfe FG, Hughes JM, Armour CL, Sewell WA. Inhibition of interleukin-5 gene expression by dexamethasone. Immunology 1992; 77: 494-9.
56. 56. Wang Y, Campbell HD, Young IG. Sex hormones and dexamethasone modulate interleukin-5 gene expression in T lymphocytes. J. Steroid Biochem. Mol. Biol. 1993; 44: 203-10.
57. 57. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 1994; 91: 752-6.
58. 58. Mukaida N, Morita M, Ishikawa Y et al. Novel mechanism of glucocorticoid-mediated gene repression: NF-κB is target for glucocorticoid-mediated interleukin 8 gene repression. J. Biol. Chem. 1994; 269: 13289-95.
59. 59. Slavin J, Unemon E, Hunt TK, Amento E. Monocyte chemotactic protein-1 (MCP-1) mRNA is down-regulated in human dermal fibroblasts by dexamethasone: differential regulation by TGF-β. Growth Factors 1995; 12: 151-7.
60. 60. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating IκB-α and inhibiting NF-κB. Am. J. Physiol. 1997; 273: 1290-6.
61. 61. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286-90.
62. 62. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκB-α in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
63. 63. Brostjan C, Anrather J, Csizmadia V et al. Glucocorticoidmediated repression of NF-κB activity in endothelial cells does not involve induction of IκBα synthesis. J. Biol. Chem. 1996; 271: 19612-6.
64. 64. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. IκB-α independent downregulation of NF-κB activity by gluα cocorticoid receptor. EMBO J. 1997; 16: 4698-707.
65. 65. Vayssiere BM, Dupont S, Choquart A et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 1997; 11: 1245-55.
66. 66. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353: 883-7.
67. 67. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of NF-κB activation in intact cells. J. Exp. Med. 1992; 175: 1181-94.
68. 68. Brennan P, O'Neill LAJ. 2-Mercaptoethanol restores the ability of nuclear factor kappa B (NF-κB) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Biochem. J. 1996; 320: 975-81.
69. 69. Ziegler-Heitbrock HW, Sternsdorf T, Liese J et al. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. J. Immunol. 1993; 151: 6986-93.
70. 70. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 1999; 56: 118-34.
71. 71. Wang Y, Rangan GK, Tay YC, Harris DC. Induction of monocyte chemoattractant prorein-1 by albumin is mediated by nuclear factor kappaB in proximal tubule cells. J. Am. Soc. Nephrol. 1999; 10: 1204-13.
72. 72. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy: Canadian Glomerulonephritis Study Group. Kidney Int. 1995; 47: 1130-5.
73. 73. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43: 1377-84.
74. 74. Hughes K, Antonsson A, Grundstrøm T. Calmodulin dependence of NFkappaB activation. FEBS Lett. 1998; 441: 132-6.
75. 75. Kalli K, Huntoon C, Bell M, McKean DJ. Mechanism responsible for T-cell antigen receptor-and CD28-or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Mol. Cell. Biol. 1998; 18: 3140-8.
76. 76. Tomita N, Morishita R, Hashizume M et al. Feasibility of decoy strategy by targeting the transcription factor NF-κB in anti-GBM nephritis (abstract). J. Am. Soc. Nephrol. 1997; 8: 467.
77. 77. Ono S, Date I, Onoda K et al. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy. Hum. Gene Ther. 1998; 9: 1003-11.
78. 78. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nature Med. 1996; 2: 998-1004.
79. 79. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of NF-κB. J. Clin. Invest. 1998; 101: 1163-74.
80. 80. Alpert D, Schwenger P, Han J, Vilcek J. Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IkappaB phosphorylation and NF-kappaB activation. J. Biol. Chem. 1999; 274: 22176-83.
81. 81. Iñiguez MA, Punzón C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors. J. Immunol. 1999; 163: 111-9.
82. 82. Venkataraman L, Burakoff SJ, Sen R. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J. Exp. Med. 1995; 181: 1091-9.
83. 83. Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J. Immunol. 1995; 155: 2427-36.
84. 84. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77, 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J. Immunol. 1999 • 162: 2095-102.
85. 85. Muraoka K, Fujimoto K, Sun X et al. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF) -kappa (B). Implications for FK506 nephropathy. J. Clin. Invest. 1996; 97: 2433-9.
86. 86. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J. 1995; 9: 899-909.